---
title: "CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 8-K: FY2025 Q2 EBIT: USD -4.65 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253647628.md"
datetime: "2025-08-19T12:53:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253647628.md)
  - [en](https://longbridge.com/en/news/253647628.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253647628.md)
generator: "portal-rs"
---

# CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 8-K: FY2025 Q2 EBIT: USD -4.65 M

EBIT: As of FY2025 Q2, the actual value is USD -4.65 M.

### Cash and Working Capital

As of June 30, 2025, Cingulate had approximately $8.9 million in cash and cash equivalents, a decrease of $3.3 million from December 31, 2024. The company expects its cash will satisfy its capital needs into late 2025 under the current business plan. To advance the commercialization efforts for CTx-1301 into early 2026, the company will need to raise approximately $1.5 million of additional capital.

### Research and Development Expenses

Research and development expenses were $2.7 million for the three months ended June 30, 2025, an increase of $0.8 million or 43.6% from the same period in 2024. This increase was due to higher clinical and regulatory costs related to the NDA submission of CTx-1301, partially offset by a decrease in manufacturing costs.

### General and Administrative Expenses

General and administrative expenses were $1.9 million for the three months ended June 30, 2025, an increase of $0.6 million or 47.1% from the same period in 2024, primarily due to higher legal and financial advisory fees.

### Net Loss

Net loss was $4.8 million for the three months ended June 30, 2025, compared to $3.2 million for the same period in 2024. The increase in net loss was primarily due to increased research and development costs.

### Outlook / Guidance

Cingulate anticipates an FDA decision in Q4 2025 regarding the NDA acceptance for CTx-1301, with a potential PDUFA date in mid-2026. The company plans to prioritize pre-commercial activities in anticipation of the launch of CTx-1301 in mid-2026, pending FDA approval.

### Related Stocks

- [CINGW.US](https://longbridge.com/en/quote/CINGW.US.md)

## Related News & Research

- [Intuit Stock Falls Ahead of Q4 Earnings: What Investors Need to Know](https://longbridge.com/en/news/296933970.md)
- [Anthropic expected to tell investors it sees over $30 trillion in potential revenue, WSJ reports](https://longbridge.com/en/news/296941513.md)
- [Bankers are shopping Hugging Face at triple the price it gave Nvidia](https://longbridge.com/en/news/296947134.md)
- [Wearable Devices Files First-Half 2026 Results and Corporate Update](https://longbridge.com/en/news/296836359.md)
- [Z3 Capital Partners LLC Buys 1,160 Shares of Meta Platforms, Inc. $META](https://longbridge.com/en/news/296881717.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**